Keio Innovation Initiative

LIFESCAPES is a research and manufacturing company specializing in brain-computer interface equipment, particularly for neurorehabilitation. The company's technology focuses on aiding stroke patients by enhancing brain plasticity, which allows individuals to overcome limitations and improve their quality of life. LIFESCAPES' devices are designed to extract and analyze brain-wave data in real-time, monitoring the activity of the functional compensation circuits in stroke patients. This innovative approach enables healthcare professionals to assist patients in regaining movement and addressing movement disorders, ultimately facilitating a more normal and fulfilling life for those affected.

FingerVision consists of specialists in this field to generate robot motions. The company solves social issues by putting advanced visual and haptic technology from universities into practice and expanding the application areas of robots and machines.

Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.

Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Luxonus is a medical device manufacturing company that offers new imaging device with optical ultrasonic technology.

Grace Imaging is a development of advanced fatigue measurement service by lactic acid sensing in sweat and MRI technologies.

Heartseed has set a mission to “open the door to heart disease treatment with regenerative medicine” and is working toward the day-to-day clinical application of myocardial regenerative medicine.

B dot Medical creates ultra-compact proton beam cancer therapy equipment. B dot Medical provides scanning irradiation, magnet design, gantry, and treatment couch features. B dot Medica creates an ultra-compact proton therapy system that defies conventional cancer treatment wisdom.

Connect Japan is developing services that connect people.

AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.

Founded in 2020, Skygate Technologies is building a network to deliver a large volume of data from observation satellites around the Earth to the ground and integrating the network into the web architecture. “Make Space accessible on the Web” is its motto, and the ability to develop both hardware and software is its strength. More information about Skygate Technologies can be found at www.skygate-tech.com.

Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.

Bonx provides wearable outdoor sports group-talk technology. Bonx creates and develops Bonx Grip, a water and shock proof unit that enables group conversations between outdoor athletes.

APB specializes in the research, development, manufacturing, and sales of lithium-ion batteries. They use polymer instead of metal for current collectors and active materials are coated with dedicated polymer materials. They offer lithium-ion batteries and all-polymer batteries for consumer, automotive, and large-scale energy storage solutions. It utilizes a polymer resin and a bipolar structure that enables the high energy density of the batteries.

Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Luxonus is a medical device manufacturing company that offers new imaging device with optical ultrasonic technology.

Synspective provides SAR data and remote monitoring services to government agencies. Its satellite data technology utilizes and integrates data from satellite constellations, big data, and machine learning. It provides various satellite services, including remote sensing and satellite imagery using small-sized SAR satellites that can measure human activity over a wide area on earth, regardless of time or weather.

Instalimb, Inc. is a Tokyo-based company focused on developing low-cost prosthetics and orthotics through advanced technology, specifically 3D printing and machine learning. As a pioneer in the field, Instalimb utilizes 3D-CAD and modeling software equipped with algorithms that optimize design and production processes. This innovative approach significantly reduces the cost of prosthetics to approximately one-tenth of traditional methods and shortens delivery times, allowing amputees to access high-quality, customized prosthetic solutions more quickly and affordably.

xenodata lab., In the mission "Technology proposal suggests naturally after five years", in order to make the shape of the future financial industry with novel technology, ideas February 2016 It was founded in. xenodata is a coined word that spells the idea of ​​creating heterogeneous creatures according to data, and by means of the intelligence created by the data, the meaning to pursue the substitution of human actions to the utmost is put in the meaning.

Luxonus is a medical device manufacturing company that offers new imaging device with optical ultrasonic technology.

Himuka AM Pharma is a pharmaceutical company focusing on the development of Adrenomedullin derivatives. Himuka AM Pharma creates drug candidates based on the bioactive peptide adrenomedullin (AM), which was discovered at the University of Miyazaki (formerly Miyazaki Medical College). Their drug candidates will make significant contributions to the resolution of unmet medical needs.

Bonx provides wearable outdoor sports group-talk technology. Bonx creates and develops Bonx Grip, a water and shock proof unit that enables group conversations between outdoor athletes.

CureApp, Inc., founded in 2014 and based in Tokyo, Japan, specializes in developing mobile applications aimed at treating various health conditions, particularly nicotine addiction. The company's flagship product, a nicotine addiction treatment app, was launched in February 2015 in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp is recognized as a prominent player in the digital health sector, focusing on applications that exhibit therapeutic effects against diseases. The company is actively conducting clinical trials to validate the efficacy of its applications. Additionally, CureApp's medical treatment platform allows users to keep daily activity logs, which are analyzed to identify triggers exacerbating their conditions. This technology enables patients to receive personalized guidance in managing lifestyle diseases, addressing health issues that are typically not managed by conventional medications or devices.

Tsubota Laboratory engages in research and development related to the prevention and treatment of myopia, dry eye, presbyopia, other eye diseases, and systemic diseases. They develop evidence-based solutions.

Institution for a Global Society specializes in providing innovative assessment solutions designed for educational institutions and businesses. Its offerings include GROW Academy, DxGROW, Ai GROW, and GROW360, which aim to facilitate seamless and unbiased evaluation processes. The organization employs ethical technology to foster a sustainable learning and development environment for individuals throughout their lives. Additionally, it focuses on people analytics, helping organizations identify, recruit, and develop human capital effectively. Its predictive analytics software has gained traction among various entities, including multinational corporations, government agencies, and international institutions, highlighting its commitment to enhancing human resource capabilities and promoting lifelong learning.

IDAC Theranostics, Inc. is a biotechnology company based in Tokyo, Japan, that focuses on the research, development, and production of pharmaceutical products aimed at treating various conditions, including cancer, graft-versus-host disease (GVHD), and inflammatory diseases. Founded in 2012, the company is dedicated to creating drug therapies for diseases that typically require only symptomatic treatment. IDAC collaborates with academic institutions and pharmaceutical companies in Japan and abroad to advance its research efforts. Through these partnerships, IDAC Theranostics aims to develop effective solutions for patients with unmet medical needs, enhancing the capabilities of healthcare providers and the pharmaceutical industry.

Generic Solution Corporation, founded in 2006 and based in Tokyo, Japan, specializes in software distribution services and offers a range of data analytics and artificial intelligence solutions. The company provides GS8 software, which focuses on information retrieval and machine learning, as well as distributed computing services, data model design, and comprehensive data analysis. By leveraging large-scale data analytic techniques, Generic Solution aims to assist its clients in organizing and analyzing complex information, thereby enabling them to set profit targets and achieve measurable outcomes. The company's commitment to delivering effective solutions helps enhance its customers' competitiveness in the market.

Bonx provides wearable outdoor sports group-talk technology. Bonx creates and develops Bonx Grip, a water and shock proof unit that enables group conversations between outdoor athletes.

CureApp, Inc., founded in 2014 and based in Tokyo, Japan, specializes in developing mobile applications aimed at treating various health conditions, particularly nicotine addiction. The company's flagship product, a nicotine addiction treatment app, was launched in February 2015 in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp is recognized as a prominent player in the digital health sector, focusing on applications that exhibit therapeutic effects against diseases. The company is actively conducting clinical trials to validate the efficacy of its applications. Additionally, CureApp's medical treatment platform allows users to keep daily activity logs, which are analyzed to identify triggers exacerbating their conditions. This technology enables patients to receive personalized guidance in managing lifestyle diseases, addressing health issues that are typically not managed by conventional medications or devices.

Quan Inc. develops characters and game content to smartphone platforms and offers global content distribution services. It offers more than 500 characters in the form of stamp and illustrations to national and international chat apps and smartphone platforms; creates content for social games and casual games, keyboard apps, stamp applications such as deco-based applications, and more; and performs PR and advertising services in the fields of market research and analysis, translation, specification changes, and game management. Quan Inc. was founded in 2011 and is based in Tokyo, Japan.

AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.

SENSY INC., established in November 2011 and headquartered in Tokyo, Japan, specializes in artificial intelligence technology focused on understanding human sensibilities. The company develops a personal AI that learns the unique sensitivities of individual users, facilitating transformative experiences across various aspects of life. SENSY's technology employs natural language processing to analyze diverse data sources, including images, text, music, and taste preferences. This enables businesses to implement personalized marketing strategies by allowing the AI to predict customer behaviors, such as visit timing and responses to promotions. In addition to consumer applications, SENSY provides support for launching new business-related services, catering to both business-to-consumer and business-to-business markets.